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ABCG2 is a member of the ATP binding cassette (ABC) 
transmembrane proteins that plays an important role in 
stem cell biology and drug resistance of cancer cells. In 
this study, we investigated how expression of human 
ABCG2 gene is regulated in lung cancer A549 cells. Bind-
ing of Sp1 and Sp3 transcription factors to the ABCG2 
promoter in vitro and in vivo was elucidated by electro-
phoretic mobility shift assay and chromatin immunopreci-
pitation assay. The ABCG2 promoter activity was impaired 
when Sp1 sites were mutated but was enhanced by over-
expression of Sp1 or Sp3 proteins. Knockdown of Sp1 or 
Sp3 expression by short interfering RNA significantly de-
creased the expression of ABCG2 mRNA and protein, re-
sulting in attenuated formation of the side population in 
A549 cells. In addition, Sp1 inhibition in vivo by mithramy-
cin A suppressed the percentage of the side population 
fraction and sphere forming activities of A549 cells. More-
over, inhibiting Sp1- or Sp3-dependent ABCG2 expression 
caused chemosensitization to the anticancer drug cispla-
tin. Collectively, our results demonstrate that Sp1 and Sp3 
transcription factors are the primary determinants for acti-
vating basal transcription of the ABCG2 gene and play an 
important role in maintaining the side population pheno-
type of lung cancer cells.  
 
 
INTRODUCTION 
 
ABCG2 is a member of the ATP binding cassette (ABC) trans-
porters, which uses cellular ATP to drive the transport of vari-
ous substrates including drugs, metabolites, and other com-
pounds across cell membranes (Mo and Zhang, 2012). The 
human ABCG2 gene was first cloned from doxorubicin-resis-
tant human MCF-7 breast cancer cells, and its coded protein 
contains 655 amino acids, including a single N-terminal ATP-
binding cassette, and 6 transmembrane segments (Allikmets et 
al., 1998; Doyle et al., 1998; Miyake et al., 1999). ABCG2 is a 
half-transporter, requiring dimerization or oligomerization to 
become functionally active (Kage et al., 2002; Xu et al., 2007). 
ABCG2 is widely distributed in normal tissues and highly ex-
pressed in stem cells, and identified as a molecular determinant 
of the side population (SP) phenotype, which is characterized 
by the ability to transport the fluorescent dye Hoechst 33342 
(Scharenberg et al., 2002; Zhou et al., 2001). Several previous 
reports suggested that ABCG2 is fundamental for the mainten-
ance of the stem cell phenotype and plays an important role in 
promoting proliferation and blocking differentiation of stem cells 
(Bunting, 2002). ABCG2 overexpression is also frequently ob-
served in a variety of tumor cells (Hirschmann-Jax et al., 2004), 
and the ABCG2+ subset of tumor cells are often enriched in 
cells with cancer stem-like phenotypes (Ho et al., 2007), which 
represent a population of drug resistant cells that can survive 
treatment and repopulate the tumor (Dalerba et al., 2007). 
The human ABCG2 gene is transcribed by a TATA-less 
promoter, with several putative Sp1, AP1, and AP2 sites and a 
CCAAT box (Bailey-Dell et al., 2001). Both positive and nega-
tive cis-regulatory elements have been identified in the ABCG2 
promoter, and functional hormone and hypoxia response ele-
ments upstream of the ABCG2 gene have been reported (Ee et 
al., 2004; Krishnamurthy et al., 2004; Szatmari et al., 2006). 
DNA methylation and histone modifications were reported to 
play important roles in the epigenetic regulation of ABCG2 
expression in human renal carcinoma and multidrug-resistant 
cells, respectively (To et al., 2006; 2008; Turner et al., 2006). 
The ABCG2 gene is also under posttranscriptional regulation 
by microRNAs and carries the binding sites for microRNAs 
such as hsa-miR-328, -519c, and -520h in its 3′-untranslated 
region (Pan et al., 2009; To et al., 2009; Wang et al., 2010). 
In this study, we investigated how expression of the human 
ABCG2 gene is regulated in lung cancer A549 cells and found 
that both Sp1 and Sp3 transcription factors are critical for acti-
vating basal transcription of the ABCG2 gene, and play an 
important role in maintaining the SP phenotype of lung cancer 
cells. 
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MATERIALS AND METHODS 
 
Cell culture 
A549 were purchased from the American Type Culture Collec-
tion and maintained in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and 100 U/ml penicillin/streptomycin. 
 
Electrophoretic mobility shift assays (EMSAs) 
EMSAs were performed essentially as described (Lee et al., 
2011). Oligonucleotide sequences from the human ABCG2 
promoter used as EMSA probes are shown in Fig. 1A. 
 
Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed essentially as described (Lee et 
al., 2011) using antibodies specific for Sp1 or Sp3 (Santa Cruz 
Biotechnology, Inc.). The sequences of the ABCG2 primers 
were as follows: ABCG2 proximal promoter, 5′-TTCAGCCGG 
GTCGCAGGGCGCTTAT-3′, 5′-TGGACCGCCAGAGCTGAAC 
GCAGTG-3′; ABCG2 distal, 5′-TTTCGTGTGTGTTTTCTCCA-
3′, 5′- GCTCACCCAGATAAGTGAAAAGA-3′. 
 
Plasmids 
To generate the wild type (WT) human ABCG2 promoter lucife-
rase reporter construct, we subcloned the ABCG2 gene -1058 
to +307 region 5′ to the luciferase gene between the XhoI and 
HindIII sites in the polylinker of the pGL3-Basic luciferase re-
porter vector (Promega). Site-directed mutagenesis of the ABCG2 
Sp1 sites in this plasmid was performed using the QuikChange 
kit (Stratagene). Three mutagenic primers, 5′-TGACCCTAGCC 
CCGAGGGAGTTAGGTGGTACCAGTCCTGCTGG-3′, 5′-GG 
CCCGGCAGTCGGGGCCACTAATCACCCCCTGTCGCGAA
CCCCGACCTGGGGA-3′, and 5′-TGGGGAAACCCGGGGC 
GCTGAAAAGGGGCCACTGCGTTCAGCT-3′ were used to 
introduce the indicated underlined 3-bp changes into the Sp1 
sites at -212, -119, -99, and -61, respectively. The pCMV-Sp1 
and pN3-Sp3FL were purchased from Addgene. The shRNA 
lentiviral vectors for Sp1 and Sp3 were described previously 
(Lee et al., 2011). 
 
Transient transfections and luciferase assays 
The transient transfections were performed using Effectene 
transfection reagent (QIAGEN) according to the manufacturer’s 
instructions. In each case, 8 × 104 cells in logarithmic growth 
phase were transfected with 200 ng supercoiled test plasmid 
and 10 ng pRL-SV40 as a transfection efficiency control. The 
cells were allowed to recover for 24 h at 37°C, and harvested 
and analyzed for luciferase activity using a luminometer (TD-
20/20 Luminometer; Turner Designs, Promega) and a dual 
luciferase assay system kit (Promega). 
 
Lentiviral transduction 
The 293T cells (2 × 106) were seeded onto 100-mm dishes, 
and 16 h later were transiently transfected with 1 μg lentiviral 
vector and 3 μg each packaging vector (Invitrogen Life Scien-
ces) by using Effectene (QIAGEN). Supernatants were col-
lected 48 h after transfection, and filtered through a 0.45 μM 
filter. A549 cells (2 × 105) were seeded into 24-well plates and 
spin-infected in the presence of 6 μg/ml of Polybrene® (Sigma-
Aldrich). Twenty-four hours post-infection, cells were treated 
with 2 μg/ml puromycin or G418 for 5 days to eliminate unin-
fected cells. 
 
 
Quantitative real time PCR 
Total RNA was isolated using TRIzol (Invitrogen) and first-
strand cDNAs were made using the PrimeScript RT Kit (Taka-
ra). Quantitative real time PCR was performed on a StepOne™ 
Real-Time PCR System (Applied Biosystems). The sequences 
of the primers were as follows: human ABCG2; 5′-ATGG 
ATTTACGGCTTTGCAG-3′, 5′-TCTTCGCCAGTACATGTTGC-
3′; human Sp1, 5′-GCGAGAGGCCATTTATGTGT-3′, 5′-GGC 
CTCCCTTCTTATTCTGG-3′; human Sp3, 5′-ATTCTGGAGA 
ACGCCCTTTT-3′, 5′-TATGTTTGGCAAGGTGGTCA-3′; 18S 
rRNA, 5′-CGGCTACCACATCCAAGGAA-3′, 5′-GCTGGAATT 
ACCGCGGCT-3′. 
 
Flow cytometry 
ABCG2 expression was assayed by flow cytometry using an 
antibody that specifically recognizes membrane-bound ABCG2 
epitopes (ABCG2-PE; eBioscience). SP abundance was de-
termined as described (Goodell et al., 2005) with minor modifi-
cations. Briefly, cells (1 × 106/ml) were incubated at 37°C for 60 
min with 5 μg/ml Hoechst 33342 (Sigma-Aldrich), washed, and 
resuspended in ice-cold HBSS with 2% fetal calf serum (FCS) 
and 2 μg/ml propidium iodide (Sigma-Aldrich). Fumitremorgin C 
(FTC; 10 μmol/L; Enzo Life Sciences), a potent and specific 
inhibitor of ABCG2 activity, was used as a positive control for 
the assay. Labeled cells were analyzed by flow cytometry on a 
LSRII (BD Biosciences). 
 
Sphere-forming assay 
A single cell suspension from trypsinization was cultured in 
serum-free DMEM/F12 medium with growth factors (10 ng/ml 
of EGF and bFGF) at a density of 1 × 103 cells/ml. After 10 
days, spheres were attached by adding FBS (10%), stained 
with Diff-Quick solution (Sysmex, Japan), and counted.  
 
MTT assay 
Approximately 2.0 × 103 cells were seeded into each well of a 
96-well plate. After 24 h incubation, the cells were exposed to 
various concentrations of cisplatin for 72 h. After incubation, 10 
μl MTT was added to each well and cells were further incu-
bated for 4 h, followed by 100 μl solubilization buffer overnight. 
The mixture was gently shaken for 10 min. Cell viability was 
evaluated based on absorbance at 550 nm in a Sunrise micro-
plate absorbance reader (Tecan).  
 
RESULTS 
 
Sp1 and Sp3 directly bind to the ABCG2 promoter region  
and increase ABCG2 promoter activity 
Analysis of the ABCG2 promoter region revealed several po-
tential consensus sequences for factor binding, including four 
consensus Sp1 binding sites (Yuan et al., 2004). We therefore 
performed EMSA to evaluate binding of 32P-labeled DNA 
probes that spanned these Sp1 sites by proteins from A549 
nuclear extracts. When WT probes spanning the Sp1 sites at -
212 (WT1), -119 and -99 (WT2), and -61 (WT3) (shown in Fig. 
1A) were assayed, two complexes (designated as C1 and C2) 
were detected with extracts from A549 cells, but the mutations 
of the Sp1 sites eliminated the formation of these complexes 
(Fig. 1B). The complexes generated with WT probes were 
competed by a 125-fold excess of unlabeled wild type competi-
tors, whereas mutant Sp1 oligonucleotides were not effective at 
inhibiting the formation of complexes (Figs. 1C, 1D, and 1E), 
indicating that these complexes were specific. The complexes 
formed with WT probes were evaluated for Sp1 and Sp3 using 
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A   WT1    5’-CGAGGGAGGGCGGTGGTACCAG-3’  (-220/-199) 
mt1    5’---------TTA------------3’ 
WT2    5’-GTCGGGGCCACGCCTCACCCCCGCCCGCGAACCC-3’  (-122/-89) 
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WT3    5’-GGCGCTGGGGAGGGGCCACTGC-3’  (-70/-49) 
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WT4    5’-GCTCGCCCCGCCCCGATCGAAT-3’  (Consensus)  
mt4    5’-----------tt-----------3’  
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antibodies to each protein. We found that anti-Sp1 blocked the 
formation of the C1 complex and anti-Sp3 antibodies resulted in 
a supershift of the C2 complex to generate a slower mobility 
complex, confirming the binding of Sp1 and Sp3 to these re-
gions (Figs. 1C, 1D, and 1E). We next performed chromatin 
immunoprecipitation to examine whether Sp1 and Sp3 bind to 
the endogenous ABCG2 promoter in A549 cells in vivo. As 
shown in Figs. 1F and 1G, constitutive recruitment of Sp1 and 
Sp3 to the ABCG2 proximal promoter, but not to the distal re-
gion, was observed in A549 cells. 
To evaluate the functional significance of Sp1 sites in the 
ABCG2 promoter region, we cloned the promoter region of the 
ABCG2 gene, mutated each Sp1 site alone and in combination 
in the context of the -1058 to +307 human ABCG2-luciferase 
reporter construct, and assayed the promoter activity of each 
mutant construct in A549 cells (Fig. 2A). Whereas the wild type 
construct showed strong promoter activity, selective mutation of 
the Sp1 sites at -212 (mt1) markedly decreased promoter ac-
tivity. However, selective mutations of the Sp1 sites at -119 and 
-99 (mt2) or -61 (mt3) modestly decreased promoter activities, 
although simultaneous mutations of the three Sp1 sites (mt5) 
significantly decreased promoter activity. These results suggest 
that the Sp1 site at -212 is most critical for maximal ABCG2 
promoter activity in A549 cells. To further demonstrate that the 
Sp family of transcription factors is involved in the transcription-
al regulation of human ABCG2, we co-transfected A549 cells 
with a luciferase reporter construct in the presence and ab-
sence of expression plasmids encoding Sp1 and Sp3. The 
activity of the pABCG2-1058-WT construct was markedly in-
creased in the presence of pCMV-Sp1 and pN3-Sp3FL, indicat-
ing that transcription factors Sp1 and Sp3 directly regulate the 
expression of ABCG2 (Figs. 2B and 2C). 
 
Fig. 1. Sp1 and Sp3 factors directly bind the
ABCG2 promoter. (A) Sequences of the
WT1, WT2, and WT3 probes (spanning the
-220/-199, -122/-89, -70/-49, respectively),
and consensus Sp1/Sp3 probe (WT4) used
in (Figs. 1B-1E) are shown. For mutant (mt)
probes, the mutations are shown in lower
case, and hyphens indicate identity to the
WT sequence. (B) Electrophoretic mobility
shift assay (EMSA) using wild type (WT)
and mutant (mt) probes shown in Fig. 1A
and nuclear extracts from A549 cells. (C-E)
EMSA using WT1 (C), WT2 (D), or WT3 (E)
probes and nuclear extracts from A549
cells. In lanes 2 and 3, EMSA were per-
formed in the presence of a 125-fold molar
excess of the indicated cold competitors. In
lanes 4-6, EMSA were performed in the
presence of antibodies to Sp1 and/or Sp3,
as indicated. (F, G) Sp1 and Sp3 bind to the
ABCG2 promoter in vivo. Chromatin immu-
noprecipitation (ChIP) assays were perfor-
med with A549 cells in the presence of pre-
immune serum, anti-Sp1 (F) or anti-Sp3
antibodies (G). DNA was purified and used
as a template for qRT-PCR with pairs of
primers that amplify the proximal promoter
(pro) or distal region of the ABCG2 gene.
Data are shown as mean ± SEM of results
from three experiments. 
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Sp1 and Sp3 are required for ABCG2 gene expression and  
SP phenotype 
Because Sp1 and Sp3 directly bind to the ABCG2 promoter 
region and increase ABCG2 promoter activities in transient 
transfections, we investigated whether ABCG2 gene expres-
sion is dependent on Sp1 and Sp3 using a lentiviral vector and 
RNA interference to inhibit the expression of these genes. The 
expression of Sp1 or Sp3 at mRNA and protein levels were 
markedly decreased in A549 cells infected with lentivirus con-
taining shRNA against Sp1 or Sp3, whereas expression of β-
actin protein was unaffected (Figs. 3A-3D). Strikingly, ABCG2 
mRNA and protein were significantly decreased in Sp1- or Sp3-
diminished A549 cells compared to the control cells (Figs. 3A, 
3B, 3E, and 3F). The SP phenotype is mainly mediated by 
ABCG2 in cancer cells. To investigate whether reduced ABCG2 
expression affects SP formation in Sp1- or Sp3-diminished A549 
cells, Hoechst 33342 dye exclusion assays were performed. 
The results show that control cells contain approximately 4% of 
the SP fraction which was completely blocked by FTC treat-
ment, whereas the percentage of SP drops to less than 1% in 
Sp1- or Sp3-diminished A549 cells (Figs. 3G and 3H). 
To further investigate the role of Sp1 and Sp3 transcription 
factors on ABCG2 gene transactivation, we treated A549 cells 
with mithramycin A, a drug that binds to the minor grooves of 
the GC-rich motifs of the DNA and hence blocks Sp1 binding. 
As shown in Figs. 4A and 4B, the expression of ABCG2 mRNA 
and protein was markedly decreased in A549 cells by treatment 
with mithramycin A, in a dose-dependent manner. Consistently, 
mithramycin A treatment suppressed the percentage of SP 
fraction (Fig. 4C) and sphere forming activities (Figs. 4D and 
4E), suggesting an essential role of Sp1 and Sp3 transcription 
factors in the function of ABCG2, as well as in maintaining the 
stemness of A549 cells.  
 
Inhibiting Sp1- or Sp3-dependent ABCG2 expression  
causes chemosensitization to the anticancer drug cisplatin 
To determine whether decreased expression of Sp1 or Sp3 
could sensitize A549 cells to anticancer drug-induced cytotox-
icity, we incubated either Sp1- or Sp3-diminished cells with 
cisplatin for 3 days and measured the percentage of viable cells 
using the MTT assay. In the absence of cisplatin, knockdown of 
Sp1 expression had little effect on the viability of A549 cells (Fig. 
5A), while A549 cells exhibited reduction in cellular viability after 
knockdown of Sp3 (Fig. 5B). Interestingly, both Sp1- and Sp3-
diminished A549 cells, with lower endogenous levels of ABCG2, 
exhibited significantly enhanced sensitivities to cisplatin com-
pared to the control A549 cells (Figs. 5A and 5B), demonstrat-
ing that inhibiting Sp1- or Sp3-dependent ABCG2 expression 
causes chemosensitization to the anticancer drug cisplatin. 
 
DISCUSSION 
 
In the present study, we show that Sp1 together with Sp3 di-
rectly regulated transcriptional expression of the ABCG2 gene, 
and diminished expression of Sp1 and Sp3 resulted in a dra-
matic decrease of SP formation and enhanced chemosensitivi-
ty to anticancer drug in a lung cancer cell line. Previous studies 
have shown that the ABCG2 proximal promoter region con-
tained several putative Sp1 binding sites to which the homeo-
box gene Msx2 recruits Sp1 to increase ABCG2 gene expres-
sion (Hamada et al., 2012). In addition, another group has re-
ported that increased occupancy of Sp1 within the ABCG2 
Fig. 2. Sp1 and Sp3 factors increase ABCG2
promoter activities. (A) Mutations in the Sp1/
Sp3 sites were introduced into the pABCG2-
WT construct, and luciferase (Luc) reporter 
constructs were transfected into A549 cells. 
*P < 0.05 compa-red with cells transfected 
with pABCG2- WT construct. (B, C) A549 
cells were transfected with pABCG2-WT 
construct (100 ng) together with different 
amounts (0, 100, 200, and 400 ng) of Sp1 
(B) or Sp3 vector (C). Data are shown as 
mean ± SEM of results from three experi-
ments. 
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promoter coincided with upregulation of ABCG2 and simulta-
neous mutation of five Sp1 binding sites markedly attenuated 
ABCG2 promoter activities (Zhang et al., 2012). Thus far, how-
ever, no definitive data that support Sp1 transcription factor as 
the direct regulator of the ABCG2 gene expression has been 
reported. Although it has been shown that mithramycin A, a 
known inhibitor of Sp1 binding, mediated dose-dependent de-
creases in ABCG2 expression, treatment with mithramycin A 
also resulted in decreased expression of other transcription 
factors such as AhR and Nrf (Zhang et al., 2012). This makes it 
uncertain whether Sp1 directly regulates ABCG2 gene expres-
sion. 
Several results from our study support the hypothesis that 
Sp3 together with Sp1 are required for transactivation of the 
ABCG2 gene in A549 cells. Sp3, one of the Sp1-related tran-
scription factors, is ubiquitously expressed and recognizes the 
same sequence as Sp1 (Safe and Abdelrahim, 2005). First, 
EMSA and ChIP assays showed in vitro and in vivo binding 
activity of Sp1 and Sp3 to ABCG2 promoter regions. Second, 
site-specific mutagenesis of Sp1/Sp3 binding sites significantly 
diminished ABCG2 promoter activity and increased expression 
of either Sp1 or Sp3 enhanced ABCG2 promoter activity. Third, 
specific knockdown of Sp1 or Sp3 using a shRNA lentivirus-
based system resulted in significantly diminished ABCG2 ex-
pression at both mRNA and protein levels. Fourth, treatment 
with mithramycin A, an inhibitor of Sp1/Sp3 binding, significant-
ly decreased ABCG2 expression, consistent with a previous 
report (Zhang et al., 2012).
Fig. 3. Knockdown of Sp1 or Sp3
represses ABCG2 expression and
alters the SP phenotype in A549 cells.
A549 cells were infected with lentivi-
rus expressing shRNA against Sp1
(A, C, E, and G) or Sp3 (B, D, F, and
H), and drug resistant cells were
selected. Real-time PCR was per-
formed to analyze mRNA levels of
Sp1, Sp3, and ABCG2 expression
and normalized with the 18S rRNA
level (A, B). *P < 0.05 compared with
control. Values are mean ± SEM of
results from three experiments. Whole
cell lysates were separated with
SDS/PAGE and subjected to West-
ern blotting using antibodies to Sp1,
Sp3, and actin (C, D). ABCG2 ex-
pression on the cell surface was
assayed by flow cytometry using an
antibody that specifically recognizes
membrane-bound ABCG2 epitopes
(E, F). To determine SP abundance,
cells were incubated with Hoechst
33342 dye in the absence (left pa-
nels of G, H) or presence (right pa-
nels of G, H) of fumitremorgin C
(FTC). The SP is shown as a per-
centage of the whole viable cell po-
pulation. Reactions were performed
in triplicates and were repeated three
times. 
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Fig. 4. Mithramycin A blocks the expression
of the ABCG2 gene and alters the SP pheno-
type and sphere-forming activities in A549
cells. (A) A549 cells were treated with differ-
ent amounts of mithramycin A (0, 50, 100,
and 200 nM) for 24 h. Real-time PCR was
performed to analyze mRNA levels of ABCG2
expression and normalized with the 18S
rRNA level. (B, C) A549 cells were treated
with different amounts of mithramycin A
before staining with anti-ABCG2 antibody (B)
or Hoechst 33342 dye (C), and analyzed by
flow cytometry. Reactions were done in tripli-
cate and repeated three times. (D) A549
cells were treated with different amounts of
mithramycin A and the sphere-forming assay
was performed to analyze the maintenance
of stemness in A549 cells. Representative
images of spheres (D) and quantification of
the assays (E). * indicates P < 0.05 and **
indicates P < 0.01 compared with controls.
Values are mean ± SEM of results from three
experiments. 
 
Fig. 5. The role of Sp1 and Sp3 on the che-
moresistance phenotype of A549 cells. Sp1-
diminished (A) or Sp3-diminished (B) A549
cells were treated with cisplatin (7 mM) for 72
h and cellular viability was measured by the
MTT assay. * indicates P < 0.05 and ** indi-
cates P < 0.01 compared with controls. Val-
ues are mean ± SEM of results from three
experiments. 
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The expression of the ABCG2 gene is an important determi-
nant of the SP phenotype and the SP cells in lung cancer cell 
lines were an enriched source of tumor-initiating cells with stem 
cell properties (Ho et al., 2007). Recently, phosphoinositide-3 
kinase pathway has been shown to regulate ABCG2 function in 
malignant pleural mesothelioma, and inhibiting the PI3K/Akt 
pathway strongly decreased the SP phenotype resulting in 
increased sensitivity to chemotherapeutic drug (Fischer et al., 
2012). In line with these reports, decreased expression of ABCG2 
resulting from depletion of Sp1 and Sp3 either by shRNA ap-
proaches or treatment of mithramycin A demonstrated dimi-
nished SP phenotypes. Furthermore, sphere-forming ability of 
A549 cells was suppressed by mithramycin A in a dose-
dependent manner, suggesting that Sp1 and Sp3 play an im-
portant role in maintenance of stemness of lung cancer cell 
lines through regulating ABCG2 expression. Elevated expres-
sion of ABCG2 is known to contribute to multidrug resistance in 
cancer chemotherapy (Chen et al., 2011). Depletion of Sp1 or 
Sp3 and a parallel decrease in ABCG2 expression caused 
enhanced sensitivity to cisplatin in A549 cells.  
In summary, our findings clarified the role of Sp1 and Sp3 in 
the regulation of the human ABCG2 gene and demonstrated 
that modulating the expression of ABCG2 by inhibiting Sp1 or 
Sp3 may be an alternative way to sensitize ABCG2-mediated 
drug resistance for better treatment of lung cancers. 
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